文献速递肿瘤 PET/CT核素与放射性配体治疗

99mTc-MIP-1404 SPECT/CT评估前列腺癌生化复发患者的全身肿瘤负荷及治疗反应

99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2020-01-01

本研究纳入125例前列腺癌生化复发患者行99mTc-MIP-1404 SPECT/CT,定量评估364个PSMA阳性病灶的全身PSMA肿瘤体积和全身总PSMA病变负荷,并与血清PSA及Gleason评分相关。在50例ADT或EBRT前后行SPECT/CT的患者中,TL-PSMA与生化反应的一致性(80%)高于与CT基于RECIST 1.1评估的一致性(60%)。

要点

  • 血清PSA与SUVmax、全身PSMA肿瘤体积及全身总PSMA病变负荷相关(P<0.05),在高分化和低分化肿瘤中均显著。
  • ADT前后TL-PSMA与生化反应一致性80%(κ=0.68),高于TL-PSMA与CT一致性60%(κ=0.46)及生化反应与CT一致性52%(κ=0.34)。
  • EBRT前后TL-PSMA与生化反应一致性最强(80%,κ=0.66),SPECT与CT不一致主要因SPECT可检出而CT未检出的小淋巴结转移和骨受累。

核心结论

  • 99mTc-MIP-1404 SPECT/CT是评估接受ADT或EBRT的前列腺癌生化复发患者治疗反应的有前景方法。
  • TL-PSMA评估治疗反应与血清PSA水平相关性最强,优于基于SUVmax的评估和基于CT数据及RECIST 1.1的反应评估。

研究设计与样本

  • 本研究共纳入125例前列腺癌生化复发患者,行99mTc-MIP-1404 SPECT/CT检查。
  • 对视野内全部364个PSMA阳性病灶进行定量评估,计算全身PSMA肿瘤体积和全身总PSMA病变负荷,并与血清PSA水平及Gleason评分进行相关性分析。
  • 在50例于ADT或EBRT开始前行99mTc-MIP-1404 SPECT/CT的患者亚组中,将TL-PSMA和SUVmax与基于RECIST 1.1的CT影像学反应评估及基于血清PSA水平变化的生化反应进行比较。

主要发现

  • 在具有1个及多于1个PSMA阳性病灶的患者中,血清PSA水平与SUVmax、全身PSMA肿瘤体积及全身总PSMA病变负荷相关(P<0.05)。
  • 在高分化(Gleason评分≤7)和低分化(Gleason评分≥8)肿瘤中,上述相关性均显著(P<0.05)。
  • 在ADT开始前后行99mTc-MIP-1404 SPECT/CT的患者中,SPECT衍生的TL-PSMA与生化反应的一致性为80%(95%CI 0.43-0.91;Cohen κ=0.68;P<0.05),TL-PSMA与CT的一致性为60%(95%CI 0.20-0.72;Cohen κ=0.46;P<0.05),生化反应与CT的一致性为52%(95%CI 0.07-0.61;Cohen κ=0.34;P<0.05)。
  • 在EBRT开始前后行SPECT/CT的患者中,TL-PSMA与生化反应的一致性最强(80%;95%CI 0.38-0.93;Cohen κ=0.66;P<0.05),TL-PSMA与CT的一致性为60%(95%CI 0.13-0.69;Cohen κ=0.69;P<0.05),生化反应与CT的一致性为48%(95%CI 0-0.54;Cohen κ=0.26;P=0.11)。
  • SPECT与CT之间的不一致结果最可能归因于对小淋巴结转移和骨受累评估的局限性,这些病变在SPECT上可检出而CT上未检出。

临床怎么用

  • 作者认为,99mTc-MIP-1404 SPECT/CT是评估接受ADT或EBRT的前列腺癌生化复发患者治疗反应的有前景方法。
  • 作者认为,TL-PSMA评估治疗反应与血清PSA水平相关性最强,优于基于SUVmax的评估和基于CT数据及RECIST 1.1的反应评估。

局限性

  • SPECT与CT之间的不一致结果最可能归因于对小淋巴结转移和骨受累评估的局限性,这些病变在SPECT上可检出而CT上未检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to investigate the value of Tc-MIP-1404 SPECT/CT for assessment of whole-body tumor burden and treatment response in patients with biochemical recurrence of prostate cancer who undergo androgen deprivation therapy (ADT) or external beam radiation therapy (EBRT). METHODS: A total of 125 patients with biochemical recurrence of prostate cancer underwent Tc-MIP-1404 SPECT/CT. All 364 prostate-specific membrane antigen (PSMA)-positive lesions in the field of view were assessed quantitatively to calculate PSMA-derived metabolic tumor parameters, including whole-body PSMA tumor volume and whole-body total lesion PSMA. These metrics were correlated with serum prostate-specific antigen (PSA) levels and Gleason scores. In a subset of 50 patients who underwent Tc-MIP-1404 SPECT/CT before the initiation of ADT or EBRT, TL-PSMA and SUVmax were compared with radiographic response assessment by CT based on RECIST 1.1 and to biochemical response (BR) determined by changes in serum PSA levels. RESULTS: Serum PSA levels correlated with SUVmax, whole-body PSMA tumor volume, and whole-body total lesion PSMA in patients with 1 and in those with more than 1 PSMA-positive lesion (P < 0.05). The correlations were significant for both well-differentiated (Gleason score ≤7) and poorly differentiated tumors (Gleason score ≥8) (P < 0.05). The agreement between TL-PSMA derived from SPECT and BR in patients who underwent Tc-MIP-1404 SPECT/CT before and after initiation of ADT was 80% (95% confidence interval [CI], 0.43-0.91; Cohen κ = 0.68; P < 0.05); in these patients, the agreement between TL-PSMA and CT was 60% (95% CI, 0.20-0.72; Cohen κ = 0.46; P < 0.05) and the agreement between BR and CT was 52% (0.07-0.61; Cohen κ = 0.34; P < 0.05). Comparable results were found for patients who underwent SPECT/CT before and after initiation of EBRT, with the strongest agreement between TL-PSMA and BR (80%; 95% CI, 0.38-0.93; Cohen κ = 0.66; P < 0.05) compared with the agreement between TL-PSMA and CT (60%; 95% CI, 0.13-0.69; Cohen κ = 0.69; P < 0.05) and between BR and CT (48%; 95% CI, 0-0.54; Cohen κ = 0.26; P = 0.11). Discordant findings between SPECT and CT were most likely due to limitations in the assessment of small lymph node metastases and bone involvement, which were detectable on SPECT but not on CT. CONCLUSIONS: The results of our study show that Tc-MIP-1404 SPECT/CT is a promising method for the evaluation of treatment response in patients with biochemical recurrence of prostate cancer who undergo either ADT or EBRT. TL-PSMA for assessment of treatment response has the strongest correlation with serum PSA levels, superior to SUVmax-based evaluation and response assessment based on CT data and RECIST 1.1.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmidkonz C, Götz TI, Atzinger A, et al. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2020. PMID: 32558706. doi:10.1097/RLU.0000000000003102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。